Drug
Emraclidine
Emraclidine: highest development phase Phase 2, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Emraclidine 30 mg NCT05443724 | Phase 2 | Schizophrenia |
Latest
No recent events.
Follow Emraclidine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.